Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to -$221000.0.

  • Adma Biologics' Change in Accured Expenses fell 1570.68% to -$221000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year increase of 5645.63%. This contributed to the annual value of -$1.1 million for FY2024, which is 11519.26% down from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Change in Accured Expenses is -$221000.0, which was down 1570.68% from -$2.8 million recorded in Q2 2025.
  • Adma Biologics' Change in Accured Expenses' 5-year high stood at $6.9 million during Q4 2022, with a 5-year trough of -$6.0 million in Q2 2024.
  • For the 5-year period, Adma Biologics' Change in Accured Expenses averaged around $886000.0, with its median value being $313905.0 (2022).
  • As far as peak fluctuations go, Adma Biologics' Change in Accured Expenses surged by 184039.6% in 2023, and later plummeted by 41101.04% in 2025.
  • Over the past 5 years, Adma Biologics' Change in Accured Expenses (Quarter) stood at $2.8 million in 2021, then surged by 143.96% to $6.9 million in 2022, then crashed by 61.29% to $2.7 million in 2023, then skyrocketed by 59.52% to $4.2 million in 2024, then tumbled by 105.21% to -$221000.0 in 2025.
  • Its last three reported values are -$221000.0 in Q3 2025, -$2.8 million for Q2 2025, and -$2.4 million during Q1 2025.